Peng Xiao-Dong, Dai Li-Li, Huang Chang-Quan, He Chun-Mei, Chen Li-Juan
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, 1# Keyuan Road 4, Chengdu 610041, Sichuan Province, China.
World J Gastroenterol. 2009 Oct 7;15(37):4720-5. doi: 10.3748/wjg.15.4720.
To investigate the correlation between the antifibrotic effect of baicalin and serum cytokine production in rat hepatic fibrosis.
Forty male Sprague-Dawley rats were divided randomly into four groups: normal control group, model group, baicalin-treated group, and colchicine-treated group. Except for the normal control group, all rats in the other groups were administered with carbon tetrachloride to induce hepatic fibrosis. At the same time, the last two groups were also treated with baicalin or colchicine. At the end of the 8 wk, all animals were sacrificed. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), transforming growth factor (TGF)-beta1, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-10 were measured. Liver index, hepatic hydroxyproline content and the degree of liver fibrosis were also evaluated.
The levels of ALT, AST and liver index in the baicalin-treated group were markedly lower than those in the model group (ALT: 143.88 +/- 14.55 U/L vs 193.58 +/- 24.35 U/L; AST: 263.66 +/- 44.23 U/L vs 404.37 +/- 68.29 U/L; liver index: 0.033 +/- 0.005 vs 0.049 +/- 0.009, P < 0.01). Baicalin therapy also significantly attenuated the degree of hepatic fibrosis, collagen area and collagen area percentage in liver tissue (P < 0.01). Furthermore, the levels of serum TGFbeta1, TNF-alpha and IL-6 were strikingly reduced in the baicalin-treated group compared with the model group, while the production of IL-10 was up-regulated: (TGF-beta1: 260.21 +/- 31.01 pg/mL vs 375.49 +/- 57.47 pg/mL; TNF-alpha: 193.40 +/- 15.18 pg/mL vs 260.04 +/- 37.70 pg/mL; IL-6: 339.87 +/- 72.95 pg/mL vs 606.47 +/- 130.73 pg/mL; IL-10: 506.22 +/- 112.07 pg/mL vs 316.95 +/- 62.74 pg/mL, P < 0.01).
Baicalin shows certain therapeutic effects on hepatic fibrosis, probably by immunoregulating the imbalance between profibrotic and antifibrotic cytokines.
探讨黄芩苷抗纤维化作用与大鼠肝纤维化血清细胞因子产生之间的相关性。
40只雄性Sprague-Dawley大鼠随机分为四组：正常对照组、模型组、黄芩苷治疗组和秋水仙碱治疗组。除正常对照组外，其他组大鼠均给予四氯化碳诱导肝纤维化。同时，后两组分别给予黄芩苷或秋水仙碱治疗。8周结束时，处死所有动物。检测血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、转化生长因子（TGF）-β1、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6和IL-10。还评估了肝脏指数、肝羟脯氨酸含量和肝纤维化程度。
黄芩苷治疗组的ALT、AST水平和肝脏指数明显低于模型组（ALT：143.88±14.55 U/L对193.58±24.35 U/L；AST：263.66±44.23 U/L对404.37±68.29 U/L；肝脏指数：0.033±0.005对0.049±0.009，P<0.01）。黄芩苷治疗还显著减轻了肝纤维化程度、肝组织中的胶原面积和胶原面积百分比（P<0.01）。此外，与模型组相比，黄芩苷治疗组血清TGFβ1、TNF-α和IL-6水平显著降低，而IL-10的产生上调：（TGF-β1：260.21±31.01 pg/mL对375.49±57.47 pg/mL；TNF-α：193.40±15.18 pg/mL对260.04±37.70 pg/mL；IL-6：339.87±72.95 pg/mL对606.47±130.
